● Recruiting

Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

Condition: HNSCC · OSCC · OPSCC · Sponsor: Zhujiang Hospital

PhaseN/A

Planned participants20

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaozhi LV · 02062783160 · lxzsurgeon@126.com

Always discuss trial participation with your own doctor first.

Locations (2)

Department of Stomatology, Zhujiang Hospital, Southern Medical University, Haizhu District, Guangzhou	Guangzhou, Guangdong, China	Not Yet Recruiting
Department of Stomatology, Zhujiang Hospital, Southern Medical University,Haizhu District	Guangzhou, Guangdong, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07686575